---
title: "Sanyuan Biotechnology: Received corrective measures ordered by the Shandong Securities Regulatory Bureau"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/230076170.md"
description: "Sanyuan Biotechnology announced that the company and relevant responsible persons received the \"Order for Correction Decision\" and \"Warning Letter Decision\" from the Shandong Securities Regulatory Bureau. Upon investigation, it was found that the company had insufficient basis for selecting indicators such as revenue growth rate, net operating asset growth rate, and discount rate when conducting impairment testing on long-term equity investments at the end of 2023. Some indicators were inappropriately selected, and issues such as not considering the proportion of equity held were identified, violating relevant accounting standards and information disclosure management measures. The Shandong Securities Regulatory Bureau decided to take corrective measures against the company and issued warning letters to Chairman Nie ZaiJian, General Manager Cheng BaoHua, and Chief Financial Officer Yu JunLing"
datetime: "2025-02-28T10:54:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/230076170.md)
  - [en](https://longbridge.com/en/news/230076170.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/230076170.md)
generator: "portal-rs"
---

# Sanyuan Biotechnology: Received corrective measures ordered by the Shandong Securities Regulatory Bureau

On February 28th, Jinshi Data reported that Sanyuan Biotechnology announced that the company and relevant responsible persons received the "Order for Correction Decision" and "Warning Letter Decision" from the Shandong Securities Regulatory Bureau. Upon investigation, it was found that when the company conducted impairment testing on long-term equity investments at the end of 2023, there were issues such as insufficient basis for selecting indicators like revenue growth rate, net operating asset growth rate, and discount rate, inappropriate selection of some indicators, and failure to consider the proportion of equity held, which violated relevant accounting standards and information disclosure management measures. The Shandong Securities Regulatory Bureau decided to take corrective measures against the company and issued warning letters to Chairman Nie ZaiJian, General Manager Cheng BaoHua, and Chief Financial Officer Yu JunLing

### Related Stocks

- [301206.CN](https://longbridge.com/en/quote/301206.CN.md)

## Related News & Research

- [11:00 ETCizzle Bio Highlights CIZ1B Biomarker Blood Test for Lung Cancer at Next Generation Dx Summit](https://longbridge.com/en/news/297064751.md)
- [Bioretec hosts media event highlighting 500,000 Activa bioresorbable orthopedic implants sold worldwide](https://longbridge.com/en/news/297047388.md)
- [Embassy Bancorp, Inc. Announces Results of Operations as of and for the Three and Six Months Ended June 30, 2026 | EMYB Stock News](https://longbridge.com/en/news/296930370.md)
- [SalesCloser ends bullVestor deal after BCSC flags promotional communications](https://longbridge.com/en/news/297012472.md)
- [Constellation’s Volaris buys Brazil cloud communications firm L5 Networks](https://longbridge.com/en/news/296784668.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**